biostudies-literatureLahusen AInstitutional funding of the Department of Internal Medicine IUniversitätsklinikum UlmServier Deutschland GmbH202https://www.ebi.ac.uk/biostudies/studies/S-EPMC12281745biostudies-literatureUnknown24(1)<h4>Background</h4>Prognosis in advanced pancreatic ductal adenocarcinoma (aPDAC) is particularly poor, only few patients benefit from treatment, and there are few biomarkers. The PREDICT trial examined whether first-line time-to-treatment failure (TTF1) predicts second-line treatment failure (TTF2) in aPDAC patients but found no association. We hypothesized that the tumor immune microenvironment (TiME) could correlate with the outcome in this trial and assessed whether tissue features were reflected in peripheral blood.<h4>Methods</h4>PREDICT patients received 5-FU/LV plus nanoliposomal irinotecan as second-line treatment. We stratified patients by shortest vs. longest TTF2 and analyzed 20 treatment-naïve tumor tissues samples via transcriptomics and immunohistochemistry. Peripheral bloodMolecular cancerAn immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial.PMC12281745PREDICTBudczies JEiseler TSeufferlein TStenzinger ASchwarzer AHofling SKarthaus MLahusen ASiegler GBecher ALutz MPAlbus SKirchner MCheung PFKluck KEttrich TJFang RKleger ASiveke JTTannapfel AfalseAn immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial.<h4>Background</h4>Prognosis in advanced pancreatic ductal adenocarcinoma (aPDAC) is particularly poor, only few patients benefit from treatment, and there are few biomarkers. The PREDICT trial examined whether first-line time-to-treatment failure (TTF1) predicts second-line treatment failure (TTF2) in aPDAC patients but found no association. We hypothesized that the tumor immune microenvironment (TiME) could correlate with the outcome in this trial and assessed whether tissue features were reflected in peripheral blood.<h4>Methods</h4>PREDICT patients received 5-FU/LV plus nanoliposomal irinotecan as second-line treatment. We stratified patients by shortest vs. longest TTF2 and analyzed 20 treatment-naïve tumor tissues samples via transcriptomics and immunohistochemistry. Peripheral blood2025-01-01T00:00:00Z2025 Jul2026-07-15T06:25:39.019Z2025-08-12T03:05:03.339ZS-EPMC122817454069645310.1186/s12943-025-02406-7